eli lilly & co (LLY:New York)
Transactions by ELI LILLY & CO (LLY) in the last 6 months
Eli Lilly and Company (NYSE:LLY) announces a share repurchase program. Under the program, the Company will repurchase up to $5 billion worth of its shares, at prevailing prices. The repurchases will be made over a period of time. The Board of Eli Lilly and Company have authorized a buyback plan on October 3, 2013. On October 3, 2013, the company initiated a Market Repurchase.
Transition Therapeutics Inc. (TSX:TTH) acquired worldwide development Rights to TT-601 from Eli Lilly and Company (NYSE:LLY) on July 23, 2013. As per the terms of the agreement, Transition Therapeutics will be obligated to pay a low single-digit royalty to Eli Lilly on net sales of TT-601. However, post review of proof-of-concept study data, Eli Lilly has an option to reacquire TT-601 rights. In case Eli Lilly exercises this option, Transition Therapeutics will be eligible ...
|AbbVie Inc||$51.35 USD||+1.59|
|Amgen Inc||$114.12 USD||+0.77|
|AstraZeneca PLC||3,489 GBp||+19.00|
|Takeda Pharmaceutical Co Ltd||¥5,070 JPY||+75.00|
|Teva Pharmaceutical Industries Ltd||$39.65 USD||-0.28|
|View Industry Companies|
Post a JobJobs
- Indianapolis, IN | ELI LillyPosted: Sep 26
- Tallahassee, FL | ELI Lilly and CompanyPosted: Dec 07
- College, AK | ELI LillyPosted: Dec 04
- San Diego, CA | ELI LillyPosted: Dec 05